All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

JBI-802 Demonstrates Preliminary Activity in Advanced Solid Tumors

January 15th 2024

Treatment with JBI-802, the first-in-class CoREST inhibitor with dual LSD1 and HDAC6 activity was shown to be safe and active.

EU Approval Sought for Frontline Lazertinib Plus Amivantamab in EGFR+ NSCLC

January 15th 2024

An MAA seeking the approval of lazertinib plus amivantamab in the first-line treatment of adult patients with EGFR+ NSCLC has been submitted to the EMA.

Florida Cancer Specialists & Research Institute Physicians Recognized for Expertise in 2023

January 15th 2024

Florida Cancer Specialists & Research Institute physicians were recognized in 2023 by several magazines as top doctors in their local communities.

ESMO 2023 Updates in Endometrial and Cervical Cancer Give Glimpse Into Future Care

January 15th 2024

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

Male Breast Cancer Diagnosis Fuels Groundbreaking Treatment Tool

January 14th 2024

Doctors diagnosed Christopher Gregg, PhD, with stage IV metastatic breast cancer in 2018. Then, he started thinking of ways to improve his treatment.

Dana-Farber Cancer Institute and the Florez Laboratory Set to Launch Innovative Pregnancy and Lung Cancer Registry

January 14th 2024

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

Florida Cancer Specialists & Research Institute Welcomes Radiation Oncologist Bradford Perez, MD in Pasco County

January 13th 2024

Florida Cancer Specialists & Research Institute, LLC is pleased to welcome radiation oncologist Bradford Perez, MD to the statewide practice.

Sequential Neoadjuvant HER2 Blockade Plus Polychemotherapy Elicits Antitumor Activity in HER2+ Breast Cancer

January 13th 2024

Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide, followed by a taxane, concomitant with trastuzumab/pertuzumab elicited responses in patients with HER2+ breast cancer.

FDA Approves Pembrolizumab Plus Chemoradiation for FIGO 2014 Stage III to IVA Cervical Cancer

January 12th 2024

The FDA has approved pembrolizumab (Keytruda) plus chemoradiation for patients with FIGO 2014 stage III to IVA cervical cancer.

Camrelizumab With Rivoceranib Elicits PFS and OS Benefit Over Sorafenib in Unresectable HCC

January 12th 2024

Amit Mahipal, MD, discusses clinical outcomes with camrelizumab plus rivoceranib in unresectable HCC, based on data from the phase 3 CARES-310 trial.

Neoadjuvant Cemiplimab Prolongs Survival in Stage II to IV CSCC

January 12th 2024

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

Addition of Multifocal MRI-Directed SIB to SBRT Shows Acceptable Toxicity Profile in Prostate Cancer

January 12th 2024

Joshua Hurwitz, MD, shares how multifocal MRI-directed SIB plus SBRT was not linked with added toxicity vs unifocal SIB in patients with prostate cancer.

Immunotherapy for Metastatic Cancer on the Rise, Even Near End of Life

January 12th 2024

Although use of immunotherapy near the end of life has increased over time, a closer look at the benefit of this in those with advanced cancers is needed.

FDA Grants Fast Track Designation to RC88 in Platinum-Resistant Recurrent Ovarian Cancer

January 12th 2024

The FDA has granted fast-track status to RC88 for use in patients with platinum-resistant recurrent epithelial ovarian cancer.

Public Trust in Science and the Future of Cancer Care Is Crucial

January 12th 2024

Maurie Markman, MD, details how public trust is critical in the future of cancer care, diving into what leads to mistrust and misinformation today.

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

January 12th 2024

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies.

Acalabrutinib Is Not Associated With Increased Hypertension Risk in CLL

January 11th 2024

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension linked with BTK inhibitors in chronic lymphocytic leukemia.

Enzalutamide Intensifies the Activity of ADT Monotherapy and Expands Limited nmCSPC Treatment Armamentarium

January 11th 2024

Neal Shore, MD, FACS, highlights the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

NALIRIFOX Prolongs Survival With a Tolerable Safety Profile in mPDAC

January 11th 2024

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard for patients with metastatic pancreatic ductal adenocarcinoma.

Advice From Experts: Taking Care of Caregivers, Too

January 11th 2024

National Family Caregivers Month is observed every November to honor the contributions and sacrifices caregivers make to support their loved ones.